Martin Murphy
Director/Board Member bij AUTOLUS THERAPEUTICS PLC
Vermogen: 2 M $ op 31-03-2024
Profiel
Martin Patrick Murphy is the founder and currently holds the position of Chairman at Syncona Partners LLP, which was founded in 2012.
He is also the Chief Executive Officer at Syncona LLP, Chairman at Autolus Ltd., Chairman at Blue Earth Diagnostics Ltd., Chairman at Syncona Investment Management Ltd., Chairman at Azeria Therapeutics Ltd., Chairman-Supervisory Board at Anaveon AG, Director at Pulmagen Therapeutics LLP, Director at Biomodal Ltd., Non-Executive Director at Achilles Therapeutics UK Ltd., Non-Executive Director at Autolus Therapeutics Plc, Director at Quell Therapeutics Ltd., Director at Neogene Therapeutics, Inc., Director at Syncona Discovery Ltd., Director at Resolution Therapeutics Ltd., and Director at Clade Therapeutics, Inc. Dr. Murphy's former positions include Chief Executive Officer at Syncona Ltd., Chairman at Serentis Ltd., Chairman at Vantia Ltd., Director at Momenta Pharmaceuticals, Inc., Non-Executive Director at Pulmagen Therapeutics (Synergy) Ltd., Director at Oxxon Therapeutics, Inc., Director at Healthcare Brands International Ltd., Director at PregLem SA, Director at Nxera Pharma UK Ltd., Director at Xention Ltd., Non-Executive Director at Achilles Therapeutics Plc, Principal at 3i Group Plc, Partner at MVM Partners LLP (2002-2012), Member-Healthcare Investment Team at 3i Plc, and Engagement Manager at McKinsey & Co., Inc. (United Kingdom).
Dr. Murphy completed his undergraduate studies at the University of Oxford and obtained a doctorate degree from the University of Cambridge in 1994.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
SYNCONA LTD GBP
0.17% | 13-07-2023 | 1 117 873 ( 0.17% ) | 2 M $ | 31-03-2024 |
AUTOLUS THERAPEUTICS PLC
-.--% | 01-03-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Martin Murphy
Bedrijven | Functie | Begin |
---|---|---|
AUTOLUS THERAPEUTICS PLC | Director/Board Member | 01-09-2014 |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Chief Executive Officer | 01-05-2012 |
Clade Therapeutics, Inc.
Clade Therapeutics, Inc. BiotechnologyHealth Technology Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation. | Director/Board Member | - |
Resolution Therapeutics Ltd.
Resolution Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Resolution Therapeutics Ltd. operates as a macrophage cell therapy company. The company was founded on December 14, 2017 and is headquartered in London, the United Kingdom. | Director/Board Member | 26-08-2020 |
Azeria Therapeutics Ltd.
Azeria Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Azeria Therapeutics Ltd. engages in the research and development of pharmaceutical products. It develops treatments for hormone resistance that targets breast and prostate cancer patients. The company was founded by Jason Carroll in 2017 and is headquartered in Cambridge, the United Kingdom. | Chairman | - |
Syncona Discovery Ltd.
Syncona Discovery Ltd. Financial ConglomeratesFinance Part of Syncona Ltd., Syncona Discovery Ltd. is a British company that provides investment services. The private company is based in London, UK. Syncona Discovery was founded in 2013. | Director/Board Member | 17-01-2017 |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Director/Board Member | 19-03-2019 |
Anaveon AG
Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland. | Chairman | 26-02-2019 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Eerdere bekende functies van Martin Murphy
Bedrijven | Functie | Einde |
---|---|---|
░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ | ░░░░░░░░ | - |
░░░░░░ ░░░░ | ░░░░░░░░ | - |
░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Opleiding van Martin Murphy
University of Oxford | Undergraduate Degree |
University of Cambridge | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
3I GROUP PLC | Finance |
AUTOLUS THERAPEUTICS PLC | Health Technology |
ACHILLES THERAPEUTICS PLC | Health Technology |
Bedrijven in privébezit | 28 |
---|---|
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Syncona Ltd.
Syncona Ltd. Investment Trusts/Mutual FundsMiscellaneous Syncona Ltd. is a closed-end investment fund. It engages in delivering returns from investments in long and alternative investment funds across multiple asset classes and targets. The company was founded on August 14, 2012, and is headquartered in St. Peter Port, the United Kingdom. | Miscellaneous |
MVM Partners LLP
MVM Partners LLP Investment ManagersFinance MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom. | Finance |
3i Plc
3i Plc Financial ConglomeratesFinance 3i Plc operates as an private equity firm and provides investment advice. The company was founded on July 21, 1945 and is headquartered in London, the United Kingdom. | Finance |
Pulmagen Therapeutics (Synergy) Ltd.
Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Commercial Services |
Oxxon Therapeutics, Inc.
Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK. | Health Technology |
Healthcare Brands International Ltd.
Healthcare Brands International Ltd. Pharmaceuticals: MajorHealth Technology Healthcare Brands International (HBI) is a new company, established in the UK in October 2006, and participating primarily in the growing market of OTC Medicines. The company is committed to acquiring, developing and investing in differentiated healthcare products. In short it will translate innovative science into meaningful consumer brands. Funded with over £100 million of venture capital from leading international venture capital investors, the company is a team of experienced OTC blue chip business professionals with an unrivalled network of partners and contacts around the world (with particular strength in Europe). It brings core skills in consumer marketing and brand development and combine with partners providing in-market operational and regulatory expertise. It will focus on innovative products with meaningful and substantiated differentiation that meet a relevant and yet unmet or only partially met consumer need and thereby help grow the overall self-medication market. | Health Technology |
PregLem SA
PregLem SA Pharmaceuticals: MajorHealth Technology PregLem SA manufactures and markets pharmaceutical products specializing in gynecology and women's reproductive health. Its products include ESMYA, PGL2001, and PGL1001. The company was founded in June 2006 and is headquartered in Geneva, Switzerland. | Health Technology |
Serentis Ltd.
Serentis Ltd. Pharmaceuticals: MajorHealth Technology Serentis Ltd. discovered, developed and distributed pharmaceutical products. The company was founded by Tim Sharpington, Alan Rothaul, and Andy Baxter in 2006 and was headquartered in London, the United Kingdom. | Health Technology |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Health Technology |
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Commercial Services |
McKinsey & Co., Inc. (United Kingdom)
McKinsey & Co., Inc. (United Kingdom) Investment ManagersFinance Part of McKinsey & Co., Inc., McKinsey & Co., Inc. (United Kingdom) is a consulting firm that helps UK manufacturers embrace new technologies for digital transformation and leadership. The private company is based in London, UK. Ruben Schaubroeck, McKinsey Digital's new lead for the UK, Belgium, and Netherlands offices, spoke with Thomas Farrar, a manager of communications in the firm's UK office, about the importance of speed and pace for CEOs in this new growth journey. The British company works with organizations that pursue sustainability, inclusion, and economic growth, all at the same time, to achieve strategic foresight and built-in agility in the face of the COVID-19 pandemic and the new trading relationship with the EU. | Finance |
Pulmagen Therapeutics LLP
Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Health Technology |
Xention Ltd.
Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The private company is based in Newmarket, UK. Xention was founded in 2002. | Health Technology |
Biomodal Ltd.
Biomodal Ltd. Miscellaneous Commercial ServicesCommercial Services Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Health Technology |
Blue Earth Diagnostics Ltd.
Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom. | Health Services |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Syncona LLP
Syncona LLP Financial ConglomeratesFinance Syncona LLP operates as a healthcare investment company. It invests in companies which focus on gene therapy, cell therapy and patient stratification technologies. The company was founded on October 19, 2012 and is headquartered in London, the United Kingdom. | Finance |
Syncona Investment Management Ltd.
Syncona Investment Management Ltd. Investment ManagersFinance Syncona Investment Management Ltd. (Syncona) is the asset management subsidiary of Syncona Ltd. in Great Britain. Headquartered in London, the firm was co-founded by Martin Murphy alongside The Wellcome Trust. Syncona is focused on founding, building and funding a portfolio of global leaders in life science. | Finance |
Azeria Therapeutics Ltd.
Azeria Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Azeria Therapeutics Ltd. engages in the research and development of pharmaceutical products. It develops treatments for hormone resistance that targets breast and prostate cancer patients. The company was founded by Jason Carroll in 2017 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Anaveon AG
Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland. | Health Technology |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Health Technology |
Syncona Discovery Ltd.
Syncona Discovery Ltd. Financial ConglomeratesFinance Part of Syncona Ltd., Syncona Discovery Ltd. is a British company that provides investment services. The private company is based in London, UK. Syncona Discovery was founded in 2013. | Finance |
Resolution Therapeutics Ltd.
Resolution Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Resolution Therapeutics Ltd. operates as a macrophage cell therapy company. The company was founded on December 14, 2017 and is headquartered in London, the United Kingdom. | Commercial Services |
Clade Therapeutics, Inc.
Clade Therapeutics, Inc. BiotechnologyHealth Technology Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation. | Health Technology |